Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 4, 2008, Pages 426-429

  Dreicer, Robert ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Prostate cancer

Indexed keywords

ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE; HYDROCORTISONE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN;

ADVANCED CANCER; ANDROGEN DEFICIENCY; ANTIGEN SPECIFICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG FATALITY; EARLY DIAGNOSIS; EVALUATION; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; REPEATED DRUG DOSE; REVIEW; UNITED STATES;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; MITOXANTRONE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 45849097238     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.11.005     Document Type: Review

References (25)

1. Cooperberg M., Grossfeld G., Lubeck D., et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981-989
2. Shahinian V., Kuo Y., Freeman J., et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer Chemother Pharmacol 103 (2005) 1615-1624
3. Tannock I.F. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?. J Clin Oncol 3 (1985) 1013-1021
4. Tannock I., Gospodarowicz M., Meakin W., et al. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7 (1989) 590-597
5. Moore M., Osoba D., Murphy K., et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12 (1994) 689-694
6. Tannock I., Osaba D., Stackler M., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
7. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 17 (1999) 2506-2513
8. Ranganathan S., Benetatos C.A., Colarusso P.J., et al. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77 (1998) 562-566
9. Laing N., Dahllof B., Hartley-Asp B., et al. Interaction of estramustine with tubulin isotypes. Biochemistry 36 (1997) 871-878
10. Pienta K.J., and Lehr J.E. Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149 (1993) 1622-1625
11. Roth B., Yeap B., Wilding G., et al. Taxol in advanced, hormone-refractory carcinoma of the prostate. A Phase II trial of the Eastern Cooperative Oncology Group. Cancer 72 (1993) 2457-2460
12. Hudes G.R., Greenberg R., Krigel R.L., et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10 (1992) 1754-1761
13. Picus J., and Schultz M. Docetaxel as mon therapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 26 Suppl 17 (1999) 14-18
14. Tannock I., de Wit R., Berry W., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
15. Petrylak D., Tangen C., Hussain M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
16. Strother J., Beer T., and Dreicer R. Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?. Eur J Cancer 41 (2005) 954-964
17. Skowronski R., Peehl D., and Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cell lines. Cancer Res 54 (1993) 805-810
18. Beer T. ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 96 (2005) 508-513
19. Beer T., Ryan C., Venner P., et al. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 382s (2005) [Abstract]
20. Joshua A.M., Nordman I., Venkataswaran R., et al. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Intern Med J 35 (2005) 468-472
21. Michels J., Montemurro T., Murray N., et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter?. Cancer 106 (2006) 1041-1046
22. Urakami S., Yoshino T., Kikuno N., et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study. Urology 65 (2005) 543-548
23. Michels J., Montemurro T., Kollmannsberger C., et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter?. Proc Am Soc Clin Oncol 23 (2005) 405s [Abstract]
24. Oh W., Manola J., Babcic V., et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T). Proc Am Soc Clin Oncol 23 (2005) 406s [Abstract]
25. Sternberg C., Whelan P., Hetherington J., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 (2005) 2-9